Teenager stands strong against cancerous lungs.

Alectinib Offers Hope: A Teen's Victory Over Lung Cancer

Jordan Keane monogram
Jordan Keane in Health & Wellness October 2026 • 4 min read.

"How a targeted therapy provided a safe and effective path to remission for an adolescent battling advanced ALK-rearranged adenocarcinoma."


Lung cancer, particularly adenocarcinoma, is rare in adolescents, making treatment strategies challenging. When the cancer also involves a specific genetic anomaly, like the ALK rearrangement, targeted therapies become crucial. Alectinib, an ALK inhibitor, has demonstrated success in adults, but its use in younger patients is less documented.

A recent case study highlights the potential of alectinib in treating a 14-year-old girl diagnosed with stage IVB ALK-rearranged adenocarcinoma of the lung. The patient presented with typical symptoms like cough and fever, leading to a diagnosis of advanced lung cancer with metastases.

What makes this case significant is the successful application of alectinib, typically used in adults, to achieve a complete metabolic remission in this young patient. This offers hope and provides valuable data for treating similar cases in the future.

AI Search Multiple angles on this topic

ALK-Targeted Activity

PubMed records describe significant activity from ALK inhibitors such as crizotinib and alectinib in ALK-rearranged cancers. This evidence places alectinib within a targeted-treatment approach for tumors driven by anaplastic lymphoma kinase abnormalities. The source specifically identifies alectinib as an important ALK inhibitor studied in relation to adolescent lung cancer.

Current Treatment and Its Limits

Alectinib is described as first-line therapy for advanced or stage IV ALK-positive non-small-cell lung cancer. The ADAPT ALEC study is evaluating therapeutic-drug-monitoring-guided dosing against standard dosing in an international, multicenter phase IV randomized controlled trial. Its rationale includes an observed shorter median progression-free survival when steady-state minimum plasma concentrations were below 435 ng/mL. After alectinib failure, evidence supporting subsequent ALK-inhibitor regimens remains limited, while platinum-based chemotherapy has been the recommended adjuvant treatment for resectable ALK-positive disease.

From Crizotinib to Alecensa

Alectinib is characterized as a potent, orally administered, next-generation ALK inhibitor developed for ALK-rearranged non-small-cell lung cancer. One overview describes it as having 10-fold greater potency than crizotinib and reports an overall response rate of 55.4%, while another reports an overall response rate of approximately 50% and improved central nervous system control compared with crizotinib. The FDA first approved Alecensa, the brand name for alectinib, on December 11, 2015, with Genentech, Inc. listed as the company. Alectinib was designed to address limitations of earlier treatment such as crizotinib by inhibiting ALK kinase activity.

Alectinib: A Targeted Solution for ALK-Rearranged Lung Cancer

Teenager stands strong against cancerous lungs.

Anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib and alectinib have revolutionized the treatment of ALK-rearranged non-small cell lung cancers (NSCLC). These inhibitors target the ALK protein, which, when rearranged, drives the growth of cancer cells. Alectinib, a second-generation ALK inhibitor, has shown superiority over conventional chemotherapy and first-generation inhibitors like crizotinib in adult trials.

The 14-year-old patient was started on alectinib at an adult dose of 600 mg twice daily, carefully monitored by a multidisciplinary team. The rationale behind using the adult dose was based on the patient's weight (60 kg) and body surface area (1.60 m²), as well as the lack of specific pediatric dosing guidelines.

  • Significant Remission: After four weeks, CT and FDG PET/CT scans revealed significant improvements. Lymphadenopathy decreased, lung masses reduced in size, and lung metastases disappeared.
  • Complete Metabolic Response: FDG PET/CT scans showed no abnormal metabolic activity at the primary and metastatic disease sites.
  • Sustained Results: Follow-up imaging at four, six, and nine months confirmed an ongoing complete metabolic response and further reduction in the primary disease size.
AI Search Multiple angles on this topic

Expanding Evidence for Alectinib

Alectinib is approved for first-line treatment of metastatic ALK-rearranged non-small-cell lung cancer and after progression on crizotinib. In untreated patients, a cited study reported median investigator-assessed progression-free survival of nearly three years with alectinib. The global phase 3, open-label, randomized ALINA trial found that adjuvant alectinib significantly improved disease-free survival versus platinum-based chemotherapy in patients with resected ALK-positive disease. Recent commentary also identifies the optimal duration of adjuvant treatment as an ongoing question, particularly because ALK-rearranged disease typically affects younger patients and carries a high risk of central nervous system metastases.

When Treatment Falls Short

Although alectinib is described as first-line therapy for ALK-positive non-small-cell lung cancer, treatment failure remains a clinical challenge. Some guidelines recommend other ALK inhibitors after alectinib failure, but the available evidence for these sequences is limited. Real-world experience has also included early discontinuation because of disease progression and adverse effects. One study focused on this issue in the context of alectinib's high protein binding and examined whether serum albumin affects time to treatment failure.

Throughout the treatment, the patient experienced manageable adverse events, including grade 1 photosensitivity, anemia, hyperbilirubinemia, and elevated hepatic transaminases, and grade 2 ovulation pain. Importantly, she did not experience the more severe side effects often associated with alectinib, such as symptomatic bradycardia or interstitial lung disease.

The Future of Adolescent Lung Cancer Treatment

This case offers a beacon of hope for adolescents facing advanced lung cancer with ALK rearrangements. Alectinib's success in achieving and sustaining remission, coupled with manageable side effects and improved quality of life, positions it as a promising treatment option. The collaborative approach between pediatric and adult oncologists, as demonstrated in this case, is essential for delivering optimal, age-appropriate care. Further research and clinical trials are needed to establish pediatric-specific dosing guidelines and to explore the long-term efficacy and safety of alectinib in this unique patient population.

AI Search Multiple angles on this topic

Promise With Important Caveats

ALK gene rearrangements are described as driver alterations underlying the development of non-small-cell lung cancer and are identified in approximately 5% of patients with advanced disease. Studies report that alectinib significantly improves survival in ALK-rearranged non-small-cell lung cancer, while also examining how different ALK rearrangements and co-mutations affect efficacy. Expert commentary describes survival as significantly prolonged compared with a first-generation ALK inhibitor, supporting alectinib's potential as first-line treatment. However, severe adverse events are reported as a limitation to long-term clinical use.

Moving Into Earlier Disease

The FDA approved alectinib as adjuvant therapy for people with ALK-positive non-small-cell lung cancer in 2024. Alectinib had previously been approved as first-line therapy for stage 4 ALK-positive lung cancer in 2017. In the ALEX trial, a cited comparison reported progression-free survival of 34.8 months with alectinib versus 10.9 months with crizotinib, alongside better central nervous system penetrance. Current research is extending into early-stage, adjuvant, and perioperative settings, while the optimal duration of adjuvant treatment remains an active question.

A Remarkable Individual Response

A case report describes more than 62 months of progression-free survival in a patient with advanced lung adenocarcinoma treated with alectinib. The patient had both an EML4-ALK fusion and a RET p.R820H mutation. The report observed no treatment-related adverse events and described the outcome as the first reported case of such prolonged survival in ALK-positive non-small-cell lung cancer with this combination of findings. This individual experience illustrates the potential for alectinib to produce durable benefit, while remaining a single-patient case report.

Alectinib compared with crizotinib in adult trials

  • 34.1 versus 10.2 monthsIn J-ALEX, median progression-free survival was 34.1 months with alectinib and 10.2 months with crizotinib; the hazard ratio was 0.37 (95% CI 0.26–0.52).[1]

How to read the adult comparison results

Across the adult comparisons, alectinib was associated with fewer progression-or-death events and longer progression-free survival than crizotinib. These comparisons describe outcomes against another ALK inhibitor, not against no treatment.[1] [2]

Alectinib's place in adult treatment evidence

A review describes second-generation ALK inhibitors, including alectinib, as preferred first-line options in advanced disease, linking that position to activity against ALK and improved central nervous system penetration compared with crizotinib.[3]

A network meta-analysis cautions that its results are a platform for future trials rather than direct evidence supporting any one agent as a frontline choice. This qualifies how broadly comparative adult evidence can be used to make claims about treatment rankings.[4]

What evidence could clarify next

  • How well do adult efficacy and safety findings translate to younger patients, given the stated lack of younger-patient data?[5]
  • Would a better-powered overall-survival analysis show a clear difference between treatments? The J-ALEX final analysis was not fully powered for that endpoint.[1]
  • How does resistance that eventually develops during alectinib treatment affect the durability of benefit, and which subsequent approaches work in that setting?[6]

Sources

  1. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer☆ (pmc.ncbi.nlm.nih.gov)
  2. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. (www.nejm.org)
  3. Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis (pmc.ncbi.nlm.nih.gov)
  4. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer (pmc.ncbi.nlm.nih.gov)
  5. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung. (pubmed.ncbi.nlm.nih.gov)
  6. Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is alectinib, and how does it work to combat lung cancer?

Alectinib is a targeted therapy drug known as an ALK inhibitor. It works by specifically targeting the ALK protein, which, when it's rearranged due to genetic anomalies, can cause cancer cells to grow uncontrollably, particularly in cases of ALK-rearranged non-small cell lung cancers (NSCLC). By inhibiting the activity of the ALK protein, alectinib helps to slow down or stop the growth of cancer cells. Alectinib is considered a second-generation ALK inhibitor and has demonstrated better results compared to first-generation inhibitors like crizotinib.

2

What exactly is ALK-rearranged adenocarcinoma, and why is it important to identify it?

ALK-rearranged adenocarcinoma is a specific type of lung cancer, particularly adenocarcinoma, where the ALK gene has undergone a rearrangement. This rearrangement leads to the production of an abnormal ALK protein that drives the growth of cancer cells. It's significant because identifying this specific genetic anomaly allows for the use of targeted therapies like alectinib, which can precisely target the ALK protein and inhibit its activity. The identification of ALK rearrangements has revolutionized treatment approaches for this subset of lung cancers, offering more effective and personalized treatment options.

3

What does it mean when a patient achieves complete metabolic remission?

Complete metabolic remission, as determined by FDG PET/CT scans, indicates that there is no longer any detectable abnormal metabolic activity in the primary and metastatic disease sites. This means that the cancer cells are no longer actively growing or spreading in the body. Achieving complete metabolic remission is a significant treatment goal, suggesting that the therapy is highly effective in eliminating or controlling the cancer.

4

Why is targeted therapy, like the use of alectinib, so important in treating certain types of lung cancer?

Targeted therapy like alectinib is important because it offers a more precise and effective approach to cancer treatment, especially in cases with specific genetic anomalies like ALK rearrangements. Unlike traditional chemotherapy, which can affect both cancer cells and healthy cells, targeted therapies specifically target the molecules and pathways that drive cancer growth. This approach can lead to better outcomes, fewer side effects, and improved quality of life for patients. The use of targeted therapy also highlights the importance of genetic testing in cancer diagnosis to identify actionable mutations and tailor treatment accordingly.

5

Why is it important to manage adverse events when a patient is being treated with alectinib?

Managing adverse events is crucial when using treatments like alectinib. Adverse events, such as photosensitivity, anemia, hyperbilirubinemia, and elevated hepatic transaminases, need careful monitoring and management to ensure patient safety and quality of life. These side effects are typically managed with supportive care and dose adjustments, and they are an important consideration in the overall treatment plan. The ability to manage these adverse events effectively allows patients to continue benefiting from the therapeutic effects of alectinib while minimizing discomfort and potential complications.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.